<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099747</url>
  </required_header>
  <id_info>
    <org_study_id>EBMT-RACE</org_study_id>
    <secondary_id>2014-000363-40</secondary_id>
    <nct_id>NCT02099747</nct_id>
  </id_info>
  <brief_title>hATG+CsA vs hATG+CsA+Eltrombopag for SAA</brief_title>
  <acronym>RACE</acronym>
  <official_title>A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Group for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The null hypothesis of no difference in CR% at 3 months between the arms will be tested
      against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds
      ratio for arm yielded by this model.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a superiority trial aiming to increase the 3 month complete response rate. The sample
      size is calculated on the hypothesis that the experimental treatment will increase the 3
      months response rate up to 21% (by 3 folds, based on the 7% reported in Scheinberg et al
      [17]). Under these assumptions, the sample size to reject the null hypothesis is n=96
      patients for each treatment arm, increased by 4% for possibly not evaluable patients (total
      number of 200 patients, 100 each treatment arm). Statistical design for sample size
      calculation: increase from 7% (control arm) to 21% (investigational arm) in 3 month complete
      response rate (two-sided binomial test); alpha-error 0.05; power 0.8.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate</measure>
    <time_frame>3 months</time_frame>
    <description>The primary objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated AA patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to best heamatological response</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heamatological Response at 6, 12, 18 and 24 months</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of response</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse rate</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidences of clonal evolution</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of PNH population occurrence and clinical hemolytic PNH occurrence</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of discontinuation of immunosuppressive therapy</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CsA-independent hematological response at 24 months</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for transfusions and number of transfusions required from treatment</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for any supportive care</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of number of SAEs between the two arms</measure>
    <time_frame>2 year</time_frame>
    <description>To look for the safety and tolerability of the investigational treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>hATG + CsA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hATG</intervention_name>
    <arm_group_label>hATG + CsA</arm_group_label>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
    <other_name>ATGAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <arm_group_label>hATG + CsA</arm_group_label>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <arm_group_label>hATG + CsA + Eltrombopag</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of severe or very severe aplastic anemia, defined by [29]:

               -  At least two of the following:

                    -  Absolute neutrophil counts &lt;0.5 x 109/L (severe) or &lt;0.2 x 109/L (very
                       severe)

                    -  Platelet counts &lt;20 x 109/L

                    -  Reticulocyte counts &lt;60 x 109/L

               -  Hypocellular bone marrow (&lt;30% cellularity), without evidences of fibrosis or
                  malignant cells

          2. Male or female age &gt; 14 years;

          3. Written informed consent

          4. Willing and able to comply with all of the requirements and visits in the protocol

          5. Understands that they can be randomised to either treatment arm

          6. Negative pregnancy test for women of child bearing age

          7. Written acceptance to use contraception (hormonal or barrier method of birth control;
             abstinence) for the entire duration of study participation.

        Exclusion Criteria:

          1. Prior immunosuppressive therapy with ATG (horse of rabbit) or any other lymphocyte
             depleting agent (i.e., alemtuzumab)

          2. Eligibility to a sibling allogeneic stem cell transplantation

          3. Evidence of a myelodysplastic syndrome, defined by the presence of myelodysplastic
             features, excess of blasts or karyotypic abnormalities typical of MDS (according to
             revised WHO 2008 criteria) [30],, as well as other primitive marrow disease. Patients
             with diagnosis of AA with cytogenetic abnormalities which are recurrent in MDS
             (according to revised WHO 2008 criteria) [30] should be included in this category, and
             are not eligible for the study; patients with del(20q), +8 and -Y are not included in
             this category, and thus are eligible for this study. The list of karyotypic
             abnormalities which qualifies for the diagnosis of MDS are listed in the Appendix.

          4. History or clinical suspect of constitutional aplastic anemia (i.e. Fanconi Anemia
             with positive DEB/MMC test or Dyskeratosis Congenita)

          5. History of malignant tumors with active disease within 5 years from enrollment, and/or
             previous chemo-radiotherapy

          6. Previous history of stem cell transplantation

          7. Treatment with cyclosporin A unless

               -  &lt;4 weeks of cyclosporin A treatment before enrolement and

               -  wash out period of 2 weeks before enrollment

          8. CMV viremia, as defined by positive PCR or pp65 test

          9. WHO performance status â‰¥3

         10. Pregnant or breast feeding patients

         11. Patients with hepatic, renal or cardiac failure, or any other life- threatening
             concurrent disease

         12. Patients with HIV infection

         13. Patients without social health care assistance

         14. Participation in another clinical trial within 1 month before the start of this trial

         15. Patients and/or female partners of male patients not using highly effective method of
             birth control i.e. intrauterine device (IUD), hormonal (oral pill, injection,
             implants), tubal ligation or partner's vasectomy

         16. subjects with known hypersensitivity to any of the component medications

        The presence of a Paroxysmal Nocturnal Hemoglobinuria clone is not an exclusion criterion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Risitano, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II Medical School, Haematology Division, Napels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Regis Peffault de Latour, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis Hospital, Haematology Division, Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Haut-LÃ©vÃ¨que</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontchaillou Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto G. Gaslini children's Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS ca Granda Ospedale</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>`Federico II` Medical School</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Sapienza University Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU CittÃ  della Salute e della Scienza di Torino</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut CatalÃ  d'Oncologia - Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donostia Hospital</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital ZÃ¼rich</name>
      <address>
        <city>ZÃ¼rich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.ebmt.org/research/studies/race-prospective-randomized-multicenter-study-comparing-horse-antithymocyte</url>
    <description>RACE</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 6, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aplastic Anaemia</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>HATG</keyword>
  <keyword>ATGAM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

